Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MVR-C5252 |
Synonyms | |
Therapy Description |
MVR-C5252 is a oncolytic herpes simplex virus type 1 modified to express IL-12 and an antibody targeting PDCD1 (PD-1), which potentially activates an anti-tumor immune response (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MVR-C5252 | MVR C5252|MVRC5252|C5252|C-5252|C 5252 | PD-L1/PD-1 antibody 121 | MVR-C5252 is a oncolytic herpes simplex virus type 1 modified to express IL-12 and an antibody targeting PDCD1 (PD-1), which potentially activates an anti-tumor immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05095441 | Phase I | MVR-C5252 | A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma | Not yet recruiting | USA | 0 |
NCT06126744 | Phase I | MVR-C5252 | Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252 (PuMP) | Recruiting | USA | 0 |